PDCD1 and neoplasm: In this retrospective bicentric study, we report the impact of baseline patient characteristics, baseline laboratory parameters, and tumor characteristics on clinical outcome with programmed cell death protein 1 (PD-1)/PD-L1 inhibitors in a well-characterized advanced NSCLC cohort.